Global Kernicterus Treatment Market – Industry Trends and Forecast to 2030

Kernicterus Treatment Market Analysis and Size

Around the world, 60 to 80 percent of neonates have jaundice. Only 0.4 to 2.7 of every 100,000 kids in developed nations get kernicterus or acute bilirubin encephalopathy. When bilirubin levels reach this level, they spread to the brain and harm the tissues of the central nervous system. Currently, "kernicterus" refers to serious neurological harm from jaundice. But all harm caused by extreme jaundice is likewise regarded as a form or stage of kernicterus.

Data Bridge Market Research analyses that the kernicterus treatment market, which is USD 2.86 billion in 2022, is expected to reach USD 3.48 billion by 2030, at a CAGR of 2.50% from 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Kernicterus Treatment Market Scope and Segmentation  

Market Definition

Kernicterus is a kind of brain damage that is carried by high bilirubin levels in a newborn's blood. The condition is frequently connected to newborns with severe, untreated jaundice. Hearing loss and athetoid cerebral palsy may result. In addition to cerebral deficits, kernicterus may result in visual and dental problems. Early detection and treatment of jaundice can prevent kernicterus.

Kernicterus Treatment Market Dynamics

Drivers

• Demand for managing hyperbilirubinemia risks in neonates underpins lucrative avenues that will propel the market growth

The health risks of untreated or improperly managed neonatal jaundice in newborns are considerable. As a result, bilirubin meters are in high demand in hospitals and infant care. Notably, improvements in detecting newborn hyperbilirubinemia have driven market participants' development prospects. Guidelines for managing newborns at risk are continually changing in developed countries, such as the U.K., which has accelerated growth potential. To address the demand for non-invasive bilirubin metres for newborns and babies, it is noteworthy that non-invasive transcutaneous bilirubin are heavily advocated. Much of the bilirubin meters market is driven by the growing usage of technologically advanced devices in emerging nations.

• Usage of exchange transfusion therapy in the cure of kernicterus treatment will propel the market growth

The immediate and effective method of clearing the blood of the already developed bilirubin. The procedure calls for removing the baby's blood, primarily the plasma, and replacing it with citrate phosphate dextrose (CPD) stored blood that is bilirubin-free. This condition is suggested when acute bilirubin encephalopathy symptoms are present and serum bilirubin levels remain high despite efforts to lower them. An exchange transfusion is typically used to treat serum bilirubin levels greater than 20–25 mg/dL. Use an erythrocyte concentrate that matches ABO type and is Rh-negative.

Opportunities

• Increased prevalence of kernicterus

The primary variables affecting the market growth rate are the increased prevalence of kernicterus. A total of 494 babies (320 boys; mean [SD] birth weight, 3505 [527] g) out of the 992 378 live babies (958 051 term births and 34 327 near-term births) had extreme hyperbilirubinemia (50 per 100,000 babies), 6.8 babies out of 100,000 had hazardous hyperbilirubinemia and 1.3 babies out of 100,000 had kernicterus. The prevalence of hypothyroidism and urinary tract infections is another factor that would moderate the market's development rate.

Moreover, during the forecast period of 2023-2030, the market for kernicterus treatments will benefit from the increase in R&D efforts and the emergence of new markets.

Restraints/Challenges

• Side effects of kernicterus treatment will hamper the market growth

An uncommon kind of brain damage can occur in neonates with jaundice. Infants with total serum bilirubin levels of more than 30 mg/dL are at an average risk of developing chronic kernicterus at a rate of roughly one in seven. Infants with bilirubin levels less than 25 mg/dL can also develop kernicterus, though it is unknown how often this condition is in the general population. These are the factors which hamper the market growth.

This kernicterus treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the kernicterus treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Kernicterus Treatment Market Scope

The kernicterus treatment market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Phototherapy
• Intravenous Immunoglobulins (IVIG)
• Blood Transfusion
• Medication
• Others

 Diagnosis

• Physical Examination
• Bilirubin Blood Test
• Others

 Symptoms

• Jaundice
• Unusual Eye Movements
• Vomiting
• Fever
• Poor Feeding
• Apnoea
• Irritability
• Seizures
• Sleepiness
• Others

 Dosage

• Injection
• Solution
• Others

Route of Administration

• Oral
• Intravenous
• Others

End-Users

• Clinic
• Hospital
• Others

 Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Kernicterus Treatment Market Regional Analysis/Insights

The kernicterus treatment market is analysed and market size insights and trends are provided by country, treatment, diagnosis, symptoms, dosage, route of administration, end-users, distribution channel as referenced above.

The countries covered in the kernicterus treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the kernicterus treatment market due to the region's substantial number of prominent actors, high level of disposable income and advanced healthcare system.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 as a result of expanded government aid, rising investment in the healthcare sector and increasing research and development efforts.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Kernicterus Treatment Market Share Analysis

The kernicterus treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to kernicterus treatment market.

Some of the major players operating in the kernicterus treatment market are:

• Bayer AG (Germany)
• Baxter (U.S.)
• Takeda Pharmaceutical Company Limited. (Japan)
• Grifols, S.A. (Japan)
• CSL Limited (Australia)
• Kedrion S.p.A (Italy)
• Biotest AG (Germany)
• China Biologic Products Holdings, Inc. (China)
• Octapharma Brasil Ltda (Switzerland)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• Sanofi (France)
• Johnson & Johnson Private Limited (U.S.)
• Abbott (U.S.)
• GSK plc (U.K.)
• Cipla Inc. (U.S.)

SKU-67350